RT Journal Article
SR Electronic
T1 Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.07.22280815
DO 10.1101/2022.10.07.22280815
A1 Li Qi
A1 Feng Yangyang
A1 Jin Yun
A1 Xi Longfu
A1 Yu Yuanquan
A1 Guo Yinghao
A1 Zhang Xiaoxiao
A1 Wu Di
A1 Li Jiangtao
YR 2022
UL http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280815.abstract
AB Introduction The mainstay treatment for intrahepatic cholangiocarcinoma is surgical resection, the impact of lymph node dissection and the scope of lymph node dissection for intrahepatic cholangiocarcinoma surgery is controversial. However, research on the comparative of regional lymphadenectomy and extended lymphadenectomy is still limited. This study will explore the effect of regional lymphadenectomy and extended lymphadenectomy in intrahepatic cholangiocarcinoma surgery patients to provide reliable evidence for further standardize the scope of lymph node dissection for intrahepatic cholangiocarcinoma surgery.Methods and analysis This is a prospective, multicentre, randomised controlled trial in intrahepatic cholangiocarcinoma surgery patients. A total of 174 patients will be enrolled at the first clinic visit in sites from China. Participants will be allocated randomly to the regional lymphadenectomy group and extended lymphadenectomy group (1:1 ratio). Patients in different groups undergo the corresponding surgery. Primary study outcome is disease-free survival (DFS). Secondary study outcomes include incidence of severe Clavien–Dindo complications (≥II), safety of operation, overall survival (OS), three-year survival rate, five-year survival rate and median mortality. Participants will be followed up at baseline, post-operation, every 3 months for the first 2 years and 6 months for the next 3 years to evaluate the impact of different surgery types. The analysis will be done according to protocol cohorts, adjusted by variables associated with intrahepatic cholangiocarcinoma.Ethics and dissemination This study was approved by the ethical review committee of the second affiliated hospital Zhejiang University school of medicine (2019-261) and will provide reference for standardize the scope of lymph node dissection for intrahepatic cholangiocarcinoma surgery.Trial registration ClinicalTrials.gov, NCT04078230. Registered on September 6, 2019. The study is expected to last for more than five years, and the first patient was enrolled on August 22, 2020, and a total of 17 patients have been enrolled so far.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT 04078230Funding StatementThis study was supported by grants from The Second Affiliated Hospital of Zhejiang University Medical College (RCT-2019-018B).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been reported to the Human Research Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine, and has been approved after the comprehensive review and risk assessment of the Committee.In the course of the study, you can contact the Human Research Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine for ethics and rights matters. Tel.: Daytime 0571-87783759; Evening: 13757118366; e-mail address: HREC2013@126.comI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is an open access article distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY- NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non- commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/